European Respiratory Society, 2023
Efzofitimod: A Novel Therapeutic Candidate for SSc-ILD
European Respiratory Society, 2023
EFZO-FIT™: A Phase 3 Study of Efzofitimod, a Novel Immunomodulator for the Treatment of Pulmonary Sarcoidosis
World Association for Sarcoidosis and Other Granulomatous Disorders, 2023
Exposure-Efficacy Analysis Supports Proof of Concept for Efzofitimod in Pulmonary Sarcoidosis
American Thoracic Society, 2023
Efzofitimod, a Novel Immunomodulator for Pulmonary Sarcoidosis, Modulates Patient Inflammatory Responses Through Myeloid Cells
American Thoracic Society, 2023
Efzofitimod: A Novel Anti-Inflammatory Agent for Sarcoidosis
Baughman RP, Niranjan V, Walker G, Burkart C, Paz S, Chong YE, Siefker D, Sun E, Nangle L, Förster S, Muders MH, Farver CF, Lower EE, Shukla S, Culver DA.
Sarcoidosis, Vasculitis and Diffuse Lung Diseases (2023)
Efzofitimod for the Treatment of Pulmonary Sarcoidosis
Culver DA, Aryal S, Barney J, Hsia CCW, James WE, Maier LA, Marts LT, Obi ON, Sporn PHS, Sweiss NJ, Shukla S, Kinnersley N, Walker G, Baughman R. CHEST (2022)
A Novel Neuropilin-2 (NRP2) Antibody for Immunohistochemical Staining of Patient Tissue Samples
European Respiratory Society, 2022
Efzofitimod (ATYR1923) Treatment Reduces Pro-inflammatory Serum Biomarkers in Pulmonary Sarcoidosis Patients
American Thoracic Society, 2022
Safety and Efficacy of Efzofitimod (ATYR1923), a Novel Immunomodulator for Pulmonary Sarcoidosis: Results of a Phase 1b/2a Randomized Placebo-Controlled Trial
American Thoracic Society, 2022